Pfizer and Thermo Fisher Scientific Inc. have entered into a collaboration agreement to help increase local access to next-generation sequencing-based testing for lung and breast cancer patients.
Read More
The study’s multi-cancer early detection data show Exai’s RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
Read More
GT Molecular, Inc. is entering the cancer molecular assay market with multi-target PCR kits featuring quality control metrics.
Read More
Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases.
Read More
A new class of blood-based biomarkers could be developed into improved or orthogonal tests for predicting tumor responses to treatment.
Read More